Skip to main content
. 2018 Mar 23;175(9):1486–1503. doi: 10.1111/bph.14156

Figure 8.

Figure 8

The anti‐lipogenic effects of metformin depend on inactivation of LXRα in an AMPKα‐dependent manner. (A–D) Cas9‐NS and Cas9‐AMPKα cells were treated with metformin (Met, 2 mM), T317 (50 nM) or both overnight. Cellular lipid content was determined by Oil Red O staining with intact cells (A) and TG quantitation with total lipid extract (B). Expression of SREBP1c, FASN and AMPKα (C), PPARα and ATGL (D) was determined by Western blot, respectively, *P < 0.05, significantly different from control; NS: not significant, (n = 5); (E–G): Cas9‐NS, Cas9‐LXRα and Cas9‐LXRβ cells received treatment with metformin (Met, 2 mM), T317 (50 nM) or both overnight followed by determination of cellular lipid content by Oil Red O staining (E) and TG quantitation (F), and expression of LXRα, LXRβ, SREBP1c, FASN and ACC1 protein (G) by Western blot respectively. C, control; M, metformin; T, T317; T/M, T317 plus metformin. *P < 0.05, significantly different as indicated; NS: not significant (n = 5).